


Nasdaq 뉴스 데이터 데일리 레포트

-2023.08.01-

0. Steady Start Seen For Indonesia Stock Market

The Indonesia stock market has risen by more than 35 points in consecutive trading days, reaching a plateau of 6,930 points. The global forecast for Asian markets is cautiously optimistic, with mixed performances from European and U.S. markets. The JCI finished modestly higher on Monday, with gains from cement companies and mixed performances from financial and resource shares. Crude oil prices also climbed higher on Monday, with WTI crude futures gaining 16 percent in July. Indonesia will release June numbers for consumer prices later today, with forecasts suggesting an annual increase of 3.11 percent for overall inflation and 2.50 percent for core CPI.

기사와 관련된 주식: _




기사 출처: Zacks / 산업 분야: Technology

1. Ares Management (ARES) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ares Management reported revenue of \$792.1 million for the quarter ended June 2023, up 28.1% from the same period last year. EPS came in at \$0.90, compared to \$0.74 in the year-ago quarter. The reported revenue represents a surprise of +9.13% over the Zacks Consensus Estimate of \$725.82 million. With the consensus EPS estimate being \$0.84, the EPS surprise was +7.14%. Investors should also consider other key metrics such as revenue growth, gross margin, operating margin, and earnings per share to gain a better understanding of a company's underlying performance.

기사와 관련된 주식: ARES




기사 출처: Fintel / 산업 분야: Stocks

2. RBC Capital Reiterates Edwards Lifesciences (EW) Outperform Recommendation

RBC Capital reiterated its Outperform recommendation for Edwards Lifesciences (NYSE:EW) on August 1, 2023. The average one-year price target for the company is \$96.09, with a range from \$73.73 to \$110.25. The projected annual revenue for Edwards Lifesciences is \$5,940MM, with a projected annual non-GAAP EPS of 2.59. There are 2,077 funds or institutions reporting positions in Edwards Lifesciences, with an average portfolio weight of 0.33%. Capital International Investors holds the largest position in the company, with a 4.24% ownership stake. The put/call ratio of EW is 0.58, indicating a bullish outlook.

기사와 관련된 주식: EW




기사 출처: BNK Invest / 산업 분야: Markets, Stocks, Options


3. Noteworthy Tuesday Option Activity: LMAT, MSTR, TPC

BNK Invest analyzed options trading activity among components of the Russell 3000 index and found notable activity in LeMaitre Vascular Inc (LMAT), MicroStrategy Inc (MSTR), and Tutor Perini Corp (TPC). LMAT saw a total volume of 1,501 contracts, which is 175.6% of its average daily trading volume over the past month. MSTR saw a volume of 12,539 contracts, which is 142.6% of its average daily trading volume over the past month. TPC saw a volume of 3,687 contracts, which is 125.8% of its average daily trading volume over the past month. High volume was seen for specific options expirations for each company. For more information, visit [StockOptionsChannel.com](https://www.StockOptionsChannel.com).


기사와 관련된 주식: LMAT



기사와 관련된 주식: MSTR



기사와 관련된 주식: TPC




기사 출처: BNK Invest / 산업 분야: Markets, Stocks

4. Notable Two Hundred Day Moving Average Cross – EW

On August 1, 2023, at 11:07 am EDT, shares of Edwards Lifesciences Corp (Symbol: EW) crossed below their 200 day moving average of \$81.67, reaching a low of \$81.05 per share. The stock is currently trading down about 0.6% on the day. The chart below shows EW's one-year performance versus its 200 day moving average. The low point in EW's 52-week range is \$67.13 per share, with a high of \$107.18, compared to a last trade of \$81.58. The DMA information was sourced from TechnicalAnalysisChannel.com.

기사와 관련된 주식: EW




기사 출처: Zacks / 산업 분야: Stocks, Investing


5. LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Beat Estimates

LeMaitre Vascular (LMAT) reported quarterly earnings of \$0.37 per share, beating the Zacks Consensus Estimate of \$0.32 per share. The company's revenues were \$50.12 million, surpassing the Zacks Consensus Estimate by 3.78%. The sustainability of the stock's immediate price movement will depend on management's commentary on the earnings call. LeMaitre shares have added about 37.4% since the beginning of the year. The estimate revisions trend for LeMaitre is mixed, with a Zacks Rank #3 (Hold) for the stock. The current consensus EPS estimate is \$0.28 on \$45.93 million in revenues for the coming quarter.

기사와 관련된 주식: LMAT




기사와 관련된 주식: ACB



6. GSK : FDA Approves New Use For Jemperli Plus Chemotherapy

GSK plc (GSK,GSK.L) announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H). The expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. Until now, chemotherapy alone has been the standard of care with many patients experiencing disease progression. In the RUBY trial, Jemperli plus chemotherapy demonstrated a 71% reduction in the risk of disease progression or death versus chemotherapy in this patient population, providing a statistically significant and clinically meaningful benefit. With the FDA's approval, Jemperli is now indicated earlier in treatment in combination with chemotherapy for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. Jemperli is already approved in the US as monotherapy in adult patients with dMMR recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

기사와 관련된 주식: GSK




기사 출처: Zacks / 산업 분야: Stocks, Investing


7. Alliant Energy (LNT) to Report Q2 Earnings: What's in Store?

Alliant Energy LNT is scheduled to release second-quarter 2023 earnings on Aug 3, after market close. The company's earnings surprise was a negative 10.96% in the last reported quarter. The Zacks Consensus Estimate for second-quarter earnings per share is pegged at 59 cents, indicating a decrease of 6.4% from the year-ago quarter. The same for revenues stands at \$1.05 billion, implying a year-over-year improvement of 11.2%. However, higher interest and depreciation costs might have offset some positives in the to-be-reported quarter. The company's Earnings ESP is 0.00%, and it carries a Zacks Rank #3. Investors can consider the following players from the same sector that have the right combination of elements to post an earnings beat for the to-be-reported quarter. Atmos Energy ATO is scheduled to report fiscal third-quarter 2023 results on Aug 2, after market close, with an Earnings ESP of +6.88% and a Zacks Rank of 2. TransAlta TAC is set to report second-quarter 2023 results on Aug 4, before market open, with an Earnings ESP of +217.65% and a Zacks Rank of 3. ALLETE Inc. ALE is set to report second-quarter 2023 results on Aug 8, before market open, with an Earnings ESP of +2.56% and a Zacks Rank of 3.


기사와 관련된 주식: LNT




기사와 관련된 주식: ALE



기사와 관련된 주식: ATO



기사와 관련된 주식: TAC




기사 출처: Zacks / 산업 분야: Stocks, Investing


8. Container Store Group (TCS) Reports Q1 Loss, Misses Revenue Estimates

Container Store Group (TCS) reported a quarterly loss of \$0.21 per share, which is a surprise of -162.50% compared to the Zacks Consensus Estimate of a loss of \$0.08. The company's revenues for the quarter were \$207.11 million, missing the Zacks Consensus Estimate by 0.99%. The Zacks Rank for the stock is #3 (Hold), indicating that the shares are expected to perform in line with the market in the near future. The current consensus EPS estimate is \$0.26 on \$241.99 million in revenues for the coming quarter and \$0.26 on \$923.36 million in revenues for the current fiscal year.

기사와 관련된 주식: TCS



기사와 관련된 주식: LCUT



기사 출처: Zacks / 산업 분야: Technology

9. Compared to Estimates, OrthoPediatrics (KIDS) Q2 Earnings: A Look at Key Metrics

OrthoPediatrics reported \$39.56 million in revenue for the quarter ended June 2023, representing a year-over-year increase of 20.1%. EPS of $-\$0.19$ for the same period compares to $-\$0.17$ a year ago. The reported revenue represents a surprise of +1.16% over the Zacks Consensus Estimate of \$39.11 million. While investors closely watch year-over-year changes in headline numbers, key metrics such as revenue and EPS provide a better insight into a company's underlying performance. Comparing these metrics to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Zacks Senior Stock Strategist, Kevin Cook, named 5 hand-picked stocks with sky-high growth potential in the Artificial Intelligence sector, which is predicted to have an internet and iPhone-scale economic impact of \$15.7 Trillion by 2030.

기사와 관련된 주식: KIDS

